Research ArticleCLINICAL INVESTIGATIONS
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Meike Körner, Martin Stöckli, Beatrice Waser and Jean Claude Reubi
Journal of Nuclear Medicine May 2007, 48 (5) 736-743; DOI: https://doi.org/10.2967/jnumed.106.038679
Meike Körner
Martin Stöckli
Beatrice Waser
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 3
March 1, 2024
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Meike Körner, Martin Stöckli, Beatrice Waser, Jean Claude Reubi
Journal of Nuclear Medicine May 2007, 48 (5) 736-743; DOI: 10.2967/jnumed.106.038679
Related Articles
Cited By...
- Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
- Reply: From Mice to Humans: The Exocrine Pancreas Does Not Matter in Human GLP-1 Receptor Imaging
- Exploring the GLP-1-GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
- PET-Based Human Dosimetry of 68Ga-NODAGA-Exendin-4, a Tracer for {beta}-Cell Imaging
- Blocking of Glucagonlike Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity for {beta}-Cells in a Mouse Model of Type 1 Diabetes
- Effect of Glucose Improvement on Spirometric Maneuvers in Patients With Type 2 Diabetes: The Sweet Breath Study
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
- Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications
- Molecular imaging in the investigation of hypoglycaemic syndromes and their management
- Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink
- Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR)
- Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
- Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers
- The complexity of signalling mediated by the glucagon-like peptide-1 receptor
- GLP-1 based therapies: clinical implications for gastroenterologists
- Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
- Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study
- Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism
- Triple-Peptide Receptor Targeting In Vitro Allows Detection of All Tested Gut and Bronchial NETs
- 111In-exendin Uptake in the Pancreas Correlates With the {beta}-Cell Mass and Not With the {alpha}-Cell Mass
- Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment
- The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
- The Glucose-Dependent Insulinotropic Polypeptide Receptor: A Novel Target for Neuroendocrine Tumor Imaging--First Preclinical Studies
- Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle
- Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118-2125
- Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
- In Vivo Imaging of the Glucagonlike Peptide 1 Receptor in the Pancreas with 68Ga-Labeled DO3A-Exendin-4
- Development and Evaluation of 18F-TTCO-Cys40-Exendin-4: A PET Probe for Imaging Transplanted Islets
- PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury
- GLP1 and cancer: friend or foe?
- Effect of Glucagon-Like Peptide 2 on Hepatic, Renal, and Intestinal Disposition of 1-Chloro-2,4-dinitrobenzene
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans
- Radiopeptide Imaging and Therapy in Europe
- Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas
- Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
- {blacktriangledown}Liraglutide for type 2 diabetes?
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
- Exendin-4 Promotes Liver Cell Proliferation and Enhances the PDX-1-induced Liver to Pancreas Transdifferentiation Process